Trials / Terminated
TerminatedNCT04385849
Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19
Phase 1b, Randomized, Blinded, Placebo-controlled Study of the Safety of Therapeutic Treatment With an Immunomodulary Agent (N-803 in Adults With COVID-19
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- ImmunityBio, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1b, randomized, blinded, placebo-controlled study in adult subjects with COVID-19. This clinical trial is designed to assess the safety and immunostimulatory activity of N-803.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | N-803 | Recombinant human super agonist interleukin-15 (IL-15) complex |
| OTHER | Saline | Sterile saline solution |
Timeline
- Start date
- 2020-07-22
- Primary completion
- 2020-07-25
- Completion
- 2020-07-25
- First posted
- 2020-05-13
- Last updated
- 2024-09-05
- Results posted
- 2024-09-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04385849. Inclusion in this directory is not an endorsement.